All In Biotech

NDA 211733 · Haleon US Holdings

Advil Dual Action With Acetaminophen

Acetaminophen, Ibuprofen · Oral · Nonsteroidal Anti-inflammatory Drug

Last checked: Nov 19, 2026Latest source record: May 5, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2020

Feb 28, 2020

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1,695

325 Phase 3, 144 recruiting

FAERS reports

2,787

45 serious, 2 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 4, 2026.

Uses temporarily relieves minor aches and pains due to: headache toothache backache menstrual cramps muscular aches minor pain of arthritis

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • ADVIL DUAL ACTION WITH ACETAMINOPHEN · ACETAMINOPHEN 250MG; IBUPROFEN 125MG · TABLET, ORAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Acetaminophen" as an intervention, any sponsor and status, largest first.

All 1,695 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • product use in unapproved indication1,717
  • drug effective for unapproved indication1,591
  • drug ineffective344
  • drug effect less than expected147
  • therapeutic product effect incomplete135
  • therapeutic response unexpected90
  • drug ineffective for unapproved indication87
  • abdominal discomfort48
  • incorrect dose administered46
  • inappropriate schedule of product administration35
  • abdominal pain upper29
  • headache25

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20181
2020203
2021400
202273
20231,259
2024551
2025269
202631

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,612 on PubMed

Sponsor: Haleon US Holdings

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.